Health information is often fragmented across wearables, apps, medical records, and lab portals, making it difficult to gain a comprehensive view and allowing preventable issues to go unnoticed. Traditional general practice care is typically reactive, addressing problems only after symptoms appear.
Emerald addresses this by offering Baseline tests covering over 115 biomarkers at more than 50 UK locations, a user-friendly dashboard for tracking trends, AI alerts for potential issues, and an assigned GP who provides diagnosis, prescriptions, and personalised action plans.
Today, Emerald locked in another $1.2M in pre-seed, bringing the total to $2M. Funding was led by Boost Capital Partners, with participation from Mark Fountain (who sold HBS UK to AXA), Granatus Ventures, and several angel investors, including Premier League players. Emerald also received an Innovate UK grant and obtained full CQC registration, enabling the company to legally diagnose and prescribe.
Earlier, Emerald raised £625K, as exclusively shared with TFN.
Emerald demonstrates strong market traction, with its user base more than tripling in the six months following our beta expansion. With over 25,000 tests processed and an NPS of 80, the data confirms a robust product-market fit.
Turning data into real patient outcomes
CEO Alexander Badalyan founded Emerald in 2024, recognising that while AI offers scalability, it often lacks medical nuance, and clinicians cannot serve every patient. CMO Dr. Daniel McNally, an active NHS clinician, ensures the platform maintains high clinical standards.
The goal is to move healthcare from reactive to proactive, with real results you can track. Long-term, Emerald wants to be your go-to clinical partner for longevity, helping you stay ahead of health issues, not just react to them. Revenue comes from personal subscriptions and B2B partnerships with healthcare providers who want in on the platform.
Emerald pulls your health data into one place, adds AI insights, and layers in GP oversight for diagnosis, meds, and coaching. Badalyan tells TFN, “We are the only platform that seamlessly integrates with over 100 physical locations for bloodwork measurements and brings wearable data directly into the clinical conversation that owns outcomes on a regulatory level. Unlike fragmented tools, Emerald unifies these inputs into a single Health OS to drive preventative care.”
While Levels focuses on metabolic health and Whoop and Oura track fitness, and Torch Health operates as an AI solution, Emerald combines consumer-friendly design with clinically validated results.
What about diversity?
When we asked Baldyan about diversity, he shared, “Emerald is a small team with a massive global footprint. In a squad of just a dozen people, we represent many distinct nationalities: British, American, Armenian, Estonian, Kurdish, Somali, Australian, Greek, and others. More than half of our team are first or second-generation immigrants. We find that this background often correlates with the ‘grit’ and resilience required to operate under the extreme pressure of a high-growth healthtech startup.”
On women in tech and culture, Baldyan comments, “We currently have three brilliant women across our clinical and operational teams. Ultimately, however, we do not view diversity as a metric to be optimised, but as a byproduct of seeking the best talent. We do not discriminate on ethnicity, religion, or orientation. At Emerald, the only things that truly matter are your alignment with our mission to prevent disease and your willingness to work incredibly hard to achieve it.”
What’s next?
The fresh funding fuels UK growth, new coaching programs (coming early 2026), and more partnerships with labs and imaging centres.
Emerald’s scaling strategy includes collaborating with healthcare providers and employers to integrate its platform, pursuing direct-to-consumer outreach, and implementing targeted marketing to increase brand awareness.